Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

類似資料

• A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
  著者:: Goswami, Trishna, 等
  出版事項: (2014)
• Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
  著者:: Schiopu, Elena, 等
  出版事項: (2016)
• Rituximab in Chronic Lymphocytic Leukemia
  著者:: James, Danelle F., 等
  出版事項: (2011)
• Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
  著者:: Goldberg, Avram, 等
  出版事項: (2014)
• Single Dose of Glycoengineered Anti-CD19 Antibody (MEDI551) Disrupts Experimental Autoimmune Encephalomyelitis by Inhibiting Pathogenic Adaptive Immune Responses in the Bone Marrow and Spinal Cord while Preserving Peripheral Regulatory Mechanisms()
  著者:: Chen, Ding, 等
  出版事項: (2014)